Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier for advanced OPTIONS screeners and volatility tools. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or

Cyclacel Pharmaceuti (CYCC)

Cyclacel Pharmaceuti (CYCC)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,996
  • Shares Outstanding, K 6,287
  • Annual Sales, $ 420 K
  • Annual Income, $ -22,560 K
  • EBIT $ -16 M
  • EBITDA $ -16 M
  • 60-Month Beta 0.38
  • Price/Sales 4.95
  • Price/Cash Flow N/A
  • Price/Book N/A
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -9.40
  • Most Recent Earnings $-0.18 on 11/12/24
  • Next Earnings Date 11/11/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend 0.150 on 07/13/16
  • Sectors:

Analyst Rating / Earnings Estimates

Current Rating
See More
Hold
Based on 1 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/24
See More
  • Average Estimate -0.29
  • Number of Estimates 1
  • High Estimate -0.29
  • Low Estimate -0.29
  • Prior Year -6.23
  • Growth Rate Est. (year over year) +95.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3174 unch
on 12/20/24
0.4650 -31.74%
on 12/03/24
-0.0539 (-14.52%)
since 11/20/24
3-Month
0.3174 unch
on 12/20/24
2.4900 -87.25%
on 10/22/24
-0.6626 (-67.61%)
since 09/20/24
52-Week
0.3174 unch
on 12/20/24
4.0000 -92.07%
on 05/01/24
-2.8726 (-90.05%)
since 12/20/23

Most Recent Stories

More News
Cyclacel Pharmaceuticals Explores Strategic Alternatives to Preserve Cash and Review Potential Transactions

Cyclacel Pharmaceuticals is exploring strategic alternatives to preserve cash, including a potential transaction with investor David Lazar.Quiver AI SummaryCyclacel Pharmaceuticals, Inc. has announced...

CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces Its Exploration of Potential Strategic Alternatives and Reduction of Operating Costs

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Closes Transaction for Exercise of Existing Warrants and Issues New Warrants

Cyclacel Pharmaceuticals closed a warrant transaction, generating $2.1 million for working capital and corporate purposes.Quiver AI SummaryCyclacel Pharmaceuticals, Inc. has successfully completed a transaction...

CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces Closing of Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces Warrant Exercise Agreement to Raise Approximately $2.1 Million

Cyclacel Pharmaceuticals announces warrant exercise agreement, raising approximately $2.1 million for working capital and corporate purposes.Quiver AI SummaryCyclacel Pharmaceuticals, Inc. announced a...

CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces Exercise of Warrants for $2.1 Million Gross Proceeds

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Reports Third Quarter Financial Results and Provides Business Update

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Announces That Nasdaq Granted an Extension to Regain Compliance With the Equity Standard Rule

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals Reports New Clinical Data from Ongoing, Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)
Cyclacel Pharmaceuticals to Present New Clinical Data From Phase 2 Study of Oral Fadraciclib at the 2024 EORTC-NCI-AACR Symposium

CYCCP : 6.05 (+8.42%)
CYCC : 0.3174 (-4.11%)

Business Summary

CYCLACEL is a biopharmaceutical company dedicated to the discovery, development and commercialization of novel, mechanism-targeted drugs to treat human cancers and other serious disorders. Three orally-available Cyclacel drugs are in clinical development. Sapacitabine, a cell cycle modulating nucleoside...

See More

Key Turning Points

3rd Resistance Point 0.3717
2nd Resistance Point 0.3609
1st Resistance Point 0.3391
Last Price 0.3174
1st Support Level 0.3065
2nd Support Level 0.2957
3rd Support Level 0.2739

See More

52-Week High 4.0000
Fibonacci 61.8% 2.5932
Fibonacci 50% 2.1587
Fibonacci 38.2% 1.7242
Last Price 0.3174
52-Week Low 0.3174

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar